Becton Dickinson and Company (NYSE:BDX) dropped by -0.56 or -0.94 points during the last session to $168.35 per share. One of the highlights of the day was the net money flow figure, which stood at $9.9 million even as the stock accepted $31.09 million in upticks but rejected $21.19 million in downticks. The up/down ratio for the last observation was a 1.47. The 1-week percentage change for the stock price is registered at -0.52%.A block transaction occurred with $12.08 million in upticks and $0 million in downticks while the up/down ratio was calculated to be 0. The stock witnessed a net inflow of $12.08 million at the end of the block trade.
Currently the company Insiders own 1.6% of Becton Dickinson and Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -21.24% . Institutional Investors own 85.48% of Becton Dickinson and Company shares. During last six month period, the net percent change held by insiders has seen a change of -21.24%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Shabshab Nabil, officer (Executive Vice President) of Becton Dickinson & Co, had unloaded 5,080 shares at an average price of $168.75 in a transaction dated on June 7, 2016. The total value of the transaction was worth $857,250.
Becton Dickinson and Company (NYSE:BDX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.94 points or 0.56% at $168.35 with 716,943 shares getting traded. Post opening the session at $169.32, the shares hit an intraday low of $168.26 and an intraday high of $170.469 and the price was in this range throughout the day. The company has a market cap of $35,724 million and the number of outstanding shares have been calculated to be 212,202,000 shares. The 52-week high of Becton Dickinson and Company (NYSE:BDX) is $171.64 and the 52-week low is $128.87.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.